Dr. Andrew Nixon is currently Senior Vice President, Global Head of Biotherapeutics Discovery Research at Boehringer Ingelheim.  In this role Andy leads the organization responsible for all biologic drug discovery efforts.  Prior to joining Boehringer Ingelheim in 2017, Andy was Vice President of Biotherapeutics Discovery at Magenta Therapeutics and held roles of increasing responsibility at Dyax Corp., including serving as Vice President of Discovery Research.  Andy has been responsible for over 100 antibody discovery programs resulting in numerous clinical candidates and approved biologics.  Andy completed a post-doctoral fellowship in the laboratory of Prof. S.J. Benkovic, in the Department of Chemistry at Pennsylvania State University, where he was involved in the development of techniques to facilitate enzyme engineering.  Andy earned his Ph.D. from the University of London for studies completed at the MRC’s National Institute for Medical Research.